7 completed, 2 not yet recruiting, 1 approved for marketing, 1 enrolling by invitation. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Enrolling by invitation 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Enrolling by invitation 1 |
Follow Progeria: new trials by email Literature Review of Progeria trials Research Report on Progeria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Creating Stem Cells From a Progeria Patient's Blood to Test Candidate Treatments in the Lab Hutchinson-Gilford Progeria Syndrome | Not yet recruiting | Bundang CHA Hospital | 1 | 2026-10-01 | 2026-09-10 | |
| A Study Observing Disease Progression in a Patient With Hutchinson-Gilford Progeria Syndrome (HGPS) Hutchinson-Gilford Progeria Syndrome | Not yet recruiting | Bundang CHA Hospital | 1 | 2026-09-01 | 2026-09-24 | |
| Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) Progerinin, Lonafarnib - Hutchinson-Gilford Progeria Syndrome | Phase 2 | Completed | PRG Science & Technology Co., Ltd. | 10 | 2025-01-13 | 2026-10-02 |
| Phase I Study of Progerinin in Healthy Volunteers Progerinin, Placebo - Hutchinson-Gilford Progeria Syndrome, Werner Syndrome | Phase 1 | Completed | PRG Science & Technology Co., Ltd. | 64 | 2020-08-24 | 2021-09-22 |
| Umbilical Cord Blood Transfusion in Progeria Syndrome Umbilical Cord Blood Unit - Hutchinson-Gilford Progeria Syndrome | Phase 1 / Phase 2 | Completed | Bundang CHA Hospital | 2 | 2019-03-05 | 2020-11-04 |
| Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria Everolimus and lonafarnib - Progeria | Phase 1 / Phase 2 | Enrolling by invitation | Boston Children's Hospital | 80 | 2015-12-01 | 2026-04-02 |
| Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria Lonafarnib, Zoledronic Acid, and Pravastatin - Progeria | Phase 2 | Unknown | Boston Children's Hospital | 85 | 2009-08-01 | 2023-02-27 |
| A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria Lonafarnib, Zoledronic Acid, Pravastatin - Progeria, Hutchinson-Gilford Syndrome | Phase 2 | Completed | Boston Children's Hospital | 5 | 2009-03-01 | 2019-06-13 |
| Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid Zoledronic acid, pravastatin - Hutchinson-Gilford Progeria Syndrome | Phase 2 | Completed | Assistance Publique Hopitaux De Marseille | 15 | 2008-10-01 | 2013-07-08 |
| Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria Lonafarnib - Progeria, Hutchinson-Gilford Syndrome | Phase 2 | Completed | Monica E. Kleinman | 29 | 2007-05-01 | 2019-06-25 |
| Clinical Studies of Progeria Progeria | Completed | National Human Genome Research Institute (NHGRI) | 15 | 2004-10-14 | 2019-11-15 | |
| Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy Lonafarnib - Progeria, HGPS | Approved for marketing | Eiger BioPharmaceuticals | 2021-04-15 |
Aging, Premature (1) · Atherosclerosis (1) · Autosomal Emery-Dreifuss Muscular Dystrophy (1) · Lipodystrophy (1) · Werner Syndrome (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Genetic Diseases, Inborn (12) · Laminopathies (12) · Metabolic Diseases (12) · Metabolism, Inborn Errors (12) · Nutritional and Metabolic Diseases (12) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiovascular Diseases (1) · DNA Repair-Deficiency Disorders (1) · Lipid Metabolism Disorders (1) · Muscular Diseases (1) · Muscular Disorders, Atrophic (1) · Muscular Dystrophies (1) · Muscular Dystrophy, Emery-Dreifuss (1)
lonafarnib (6) · Pravastatin (3) · Zoledronic Acid (3) · Everolimus (1) · Sirolimus (1)
Boston Children's Hospital (3) · Bundang CHA Hospital (3) · PRG Science & Technology Co., Ltd. (2) · Assistance Publique Hopitaux De Marseille (1) · Eiger BioPharmaceuticals (1) · Monica E. Kleinman (1) · National Human Genome Research Institute (NHGRI) (1)
United States (7) · South Korea (2) · France (1)
Mark W Kieran, MD, PhD (2) · Mark Kieran, MD, PhD (1) · Min Young Kim, MD, PhD (1) · Monica Kleinman, M.D. (1) · William A Gahl, M.D. (1)
PMID 24795390, PMID 27400896, PMID 36507973, PMID 36919608, PMID 18256394, PMID 22083160, PMID 22460337, PMID 22752073, PMID 23012407, PMID 23179651, PMID 23897869, PMID 24249802
2008 (1)